Trametinib

response biomarkers — cross-omics
Drug responseDRUG → FUNCTION-MSCell lineGSK1120212, Mekinist

Across CCLE and GDSC cell-line panels, response to Trametinib is significantly associated with the protein-level pathway activity of multiple pathways, with LUNG_SCLC cell lines showing a particularly strong set of associations.

The most reproducible Trametinib response-associated pathways across cancer lineages are Mitotic nuclear division, Regulation of protein localization to plasma membrane, and Antigen processing and presentation of endogenous peptide antigen via MHC class Ib, each associated with drug response in up to 8 lineages. Since the analysis identifies associations rather than directional relationships, both response-to-biomarker and biomarker-to-response views are provided.

Each biomarker is linked to its corresponding Q-omics profile. The scatter plot shows the strongest observed association, Trametinib response versus Mitotic nuclear division protein-level pathway activity in LUNG_SCLC (Pearson r = -0.41).

Protein-level pathway activity biomarkers of Trametinib response

Ranked by combined sampling and lineage consensus. X-score (response→biomarker) and Y-score (biomarker→response) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.
Each biomarker links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Trametinib response vs Mitotic nuclear division — LUNG_SCLC

Per-cell-line scatter of Trametinib response vs Mitotic nuclear division protein-level pathway activity in LUNG_SCLC.

Explore this scatter interactively →

Exploration